Lacouture, M.E., Mitchell, E.P., Piperdi, B., Pillai, M.V., Shearer, H., Iannotti, N., . . . Yassine, M. (2010). Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28, 1351–1357.
To examine the difference in incidence of specific grade 2 or higher skin toxicities of interest between patients with metastatic colorectal cancer in preemptive and reactive skin treatment groups during a six-week treatment period that included epidermal growth factor receptor inhibitors (EGFR-Is).
Eligible patients were randomly assigned to preemptive or reactive skin treatment arms. The chemotherapy regimen schedule was a random assignment stratification factor.
The preemptive skin treatment regimen was administered beginning on day –1 (one day before the administration of the first panitumumab dose) and continued through weeks 1 to 6.
Clinical and experimental data suggest that four major alterations occur in the skin of patients treated with EGFR-Is: follicular and interfollicular inflammation, bacterial superinfection, dry skin, and sensitivity to ultraviolet (UV) radiation. The rationale for selection of the preemptive skin regimen was based on those four alterations. The preemptive skin treatment regimen comprised the following.
The reactive skin treatment regimen comprised any treatments the investigator deemed necessary for the management of emergent skin toxicity and could be administered anytime during weeks 1 to 6. Patients randomly assigned to the reactive skin treatment group were not prohibited from using skin moisturizer or sunscreen at any time during the treatment if they chose to do so.
All patients were monitored weekly from weeks 1 to 7 for compliance with the randomized skin treatment regimen and for skin toxicity assessment.
Patients were undergoing the active treatment phase of care.
This was a phase 2, multicenter, open-label, randomized clinical trial.
The preemptive skin treatment regimen was well tolerated. The incidence of specific grade 2 or higher skin toxicities during the six-week skin treatment period was lower in the preemptive skin treatment group compared with the reactive skin treatment group.
The findings supported the importance of establishing a preemptive, comprehensive skin treatment regimen in patients treated with panitumumab to decrease skin toxicities and improve QOL. The skin toxicities are considered a class-based effect; therefore, these results may be generalized to other EGFR-Is.
Lacouture, M.E., Anadkat, M.J., Bensadoun, R.-J., Bryce, J., Chan, A., Epstein, J.B., Eaby-Sandy, B., . . . MASCC Skin Toxicity Study Group. (2011). Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Supportive Care in Cancer, 19, 1079–1095.
To develop first-generation, evidence-based recommendations for eight epidermal growth factor receptor inhibitor (EGFRI)-associated dermatologic toxicities: papulopustular (acneform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis, fissures, and paronychia.
The type of patients addressed was those receiving EGFRIs.
In this guideline, topic review committees were formed according to expertise to review the literature and develop guidelines for each dermatologic toxicity. Each review committee comprised three members, with a primary reviewer to present the findings of the committee to the Skin Toxicity Study Group. Each committee reviewed from 17 to 35 articles to formulate the recommended guidelines. Randomized clinical trials were considered the best source. The level of evidence and grade of the recommendation were considered. In the absence of experimental evidence, pertinent studies and case reports were presented in conjunction with expert opinion derived from clinical practice. When available, data were extrapolated from other dermatologic conditions with similar clinical or pathologic characteristics (e.g., xerosis, alopecia, hirsutism, pruritus, paronychia, radiation dermatitis).
Databases searched were Ovid, MEDLINE, and Embase.
Search keywords were rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis, fissures, paronychia, EGFR inhibitors, and recommendations (this information was not stated directly in the article).
Studies were included in the review if they were published before December 2010.
Studies were excluded if they were published during or after December 2010.
Eight tables outlining prophylactic and reactive recommendations were included for papulopustular (acneform) rash, hair changes, radiation dermatitis, pruritus, oral complications, xerosis, fissures, and paronychia.
Papulopustular (Acneform) Rash
Preventive (Weeks 1–6 and 8 of EGFRI Initiation):
Treatment:
Hair Changes (Hair Loss)
Preventive:
Treatment:
Hair Changes (Increased Hair)
Preventive:
Radiation Dermatitis
Preventive:
Treatment:
Pruritus
Preventive:
Treatment:
Mucositis
Preventive:
Treatment:
Xerosis
Preventive:
Treatment:
Fissures
Preventive:
Treatment:
Paronychia
Preventive:
Treatment:
Recommendations were based on randomized clinical trials with control groups when possible. However, because of the lack of high-quality studies investigating EGFRI-associated dermatologic changes, many recommendations were based on expert opinion and consensus.
The authors developed first-generation, evidence-based recommendations for eight EGFRI-associated dermatologic toxicities: papulopustular (acneform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis, fissures, and paronychia. In addition, the authors rated each intervention according to the level of evidence (I–V) and the recommendation grade (A–D).
The authors proposed that multidisciplinary teams, including radiation and medical oncologists, nurses, dermatologists, pharmacists, oral healthcare providers, and wound care specialists, should assess the occurrence and management of EGFRI-associated dermatologic toxicities. In addition, the Multinational Association for Supportive Care in Cancer (MASCC) EGFRI Skin Toxicity Tool (MESTT) should be used in clinical trials and practice.
Nurses should provide patient education prior to EGFRI therapy to ensure patients can expect, prepare for, and use preventive and treatment approaches to manage the eight toxicities described. In addition, nurses should encourage the multidisciplinary team to collaborate on management of EGFRI-associated dermatologic toxicities.
Lacouture, M.E., Wolchok, J.D., Yosipovitch, G., Kähler, K.C., Busam, K.J., & Hauschild, A. (2014). Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 71, 161–169.
From pooled analysis, 64.2% of patients experienced an IRAEs of any grade, and 17.8% were severe (grade 3 or 4). Dermatologic IRAEs were the most common (44.9% any grade). Most IRAEs develop within the first 12 weeks (five to nine weeks depending on the dose). Ipilimumab rash differs from that of targeted therapies, with ipilimumab rash more closely resembling maculopapular rash. Pruritus with or without rash and can have major impact on quality of life. Ipilimumab appearance, histology, time to onset of IRAEs, grading, and management of skin IRAEs were reviewed.
Guidelines are developed to aid providers to manage IRAEs by early intervention and vigilance. First, determine the severity of the rash or pruritis. For grade 1 or 2 rash, topical corticosteroids and oral antihistamines may be useful. Resume ipilimumab with resolution of rash or with improvement if systemic steroid dose is 7.5 mg of prednisone or less. If grade 3 rash is present, hold ipilimumab and give oral corticosteroids at 1–2 mg/kg/day of prednisone or equivalent. If symptoms improve, healthcare professionals can re-challenge. If symptoms worsen or are evaluated as grade 4, permanently discontinue ipilimumab. Administer corticosteroids at a grade 3 dose and taper for one month if rash improves. For mild or localized pruritus, use topical corticosteroids and antipruritics. For intermittent intense or widespread pruritus, topical corticosteroids and oral antihistamines are indicated. If pruritus is constant, limiting self-care or sleep, use oral antihistamines and corticosteroids and consider gabapentin, pregabalin, mirtazapine, and aprepitant.
These are expert opinion guidelines developed from pooled trial data of patients with metastatic melanoma and from evaluating other clinical trial results of ipilimumab. Interventions are not developed from randomized, controlled clinical trials. These guidelines do not differentiate disease type or dose-related IRAEs.
Quality of life and optimal therapy for patients receiving these new therapies are dependent on vigilance and early detection for interventions. Patient and healthcare providers need to be instructed to recognize findings for improved outcomes early. Mechanisms for patients to report their experiences should be outlined early.
Labourey, J. L. (2007). Physical activity in the management of cancer-related fatigue induced by oncological treatments. Annales de Réadaptation et de Médecine Physique, 50, 445–459.
PubMed was searched to identify English or French language reports of randomized or controlled studies and meta-analyses concerning the benefits of physical activity in patients receiving cancer treatment. The dates encompassed by the search process were not specified.
Eleven randomized or controlled studies that had evaluated the effects of physical exercise on cancer-related fatigue as one of their primary or secondary objectives were identified for analysis. Varied patient-reported outcome measures were used to evaluate fatigue, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Piper Fatigue Scale, Functional Assessment of Cancer Therapy-Fatigue (FACT-F), or the Profile of Mood States (POMS) Fatigue-Inertia subscale. Studies evaluated aerobic exercise, strength training, or a combination of both. Supervised and home-based exercise interventions were studied, and the duration of exercise treatment ranged from only the duration of hospitalization to several months.
Of the seven studies of exercise during active cancer therapy, five studies (all with less than 25 patients) found no significant differences in fatigue across the treatment period. A sixth study in a highly selected population of patients hospitalized for stem cell transplant noted that fatigue increased significantly in the control group but remained steady in the exercise group. The seventh study of men with prostate adenocarcinoma on hormone therapy and receiving strength training noted a statistically significant improvement in fatigue in patients receiving the strength training intervention.
In the posttreatment setting, three studies with small samples suggested that exercise (aerobic exercise of low or moderate intensity) or a motivational counseling intervention to increase home-based exercise and a small study in patients with breast and colon cancer who were three to 15 months posttreatment showed significant improvement in fatigue as a result of either low- or moderate-intensity exercise, compared to controls. An additional study in patients who had completed chemotherapy or surgery within the past month showed an improvement in aerobic fitness in the intervention group but a statistically significant increase in fatigue.
Taken together, these results suggested that there is no clear evidence that exercise during active treatment improves fatigue outcomes, although it may have a favorable effect on cardiorespiratory conditioning. The results of this review point to the possibility that a minimum of rest or mild activity is needed to promote some initial recovery from treatment-related fatigue before residual fatigue is addressed, but current studies provide no guidance on how long the interval should be between the end of chemotherapy and the start of exercise for therapeutic purposes.
Kwong, K.K. (2004). Prevention and treatment of oropharyngeal mucositis following cancer therapy: Are there new approaches? Cancer Nursing, 27(3), 183–205.
Database searched was MEDLINE (1993–2003) for randomized, controlled trials evaluating mucositis interventions.
A total of 50 randomized controlled trials were presented. Other trials and papers were referenced.
The author concluded that most agents require more study.
The author noted the problem of variation in study protocols, insufficient sample sizes, and a lack of consensus regarding the scoring system for mucositis.
The author noted the need to include psychotherapeutic interventions and management and pointed out the lack of a quality-of-life tool for mucositis.
Kwiatkowski, F., Mouret-Reynier, M.A., Duclos, M., Leger-Enreille, A., Bridon, F., Hahn, T., . . . Bignon, Y.J. (2013). Long term improved quality of life by a 2-week group physical and educational intervention shortly after breast cancer chemotherapy completion. Results of the 'Programme of Accompanying women after breast Cancer treatment completion in Thermal resorts' (PACThe) randomised clinical trial of 251 patients. European Journal of Cancer, 49(7), 1530–1538.
Determine the effectiveness of an intensive intervention (i.e., two weeks at a SPA centre involving exercise, physiotherapy, and dietary education) on overall quality of life, weight, nutrition, and physical activity in women who recently had completed treatment for non-metastatic breast cancer
The intervention included a two-week stay at a SPA centre with a daily routine of physical training (i.e., two hours daily under the supervision of a physiotherapist, which included walking, strength training, and aquaexercise), dietary education with cooking lessons and provision of healthy meals, and aesthetic care, massage, etc. Dietary consultations every six months for three years also were incorporated into standard follow-up care.
PHASE OF CARE: Transition phase after active treatment
Prospective, randomized, repeated measures (baseline, 6, 12, 18, and 24 months after intervention) two-group clinical trial
Statistically significant differences were seen between groups on the SF-36 measure at six months, but these differences did not persist in any dimension at year one except for a difference in vitality at one year between groups. Although data were collected on weight/body mass index, diet, and sleep, results for these variables are not reported (except to note no significant differences in sleep between the groups). The plots/trends in quality of life over time (at 6, 12, 18, and 24 months) look very similar for both groups, except for a significant upward trend at six months for the intervention group. The correlation was stronger between HADS depression and SF-36 quality of life. In the SPA group, an overall decrease was seen in anxiety compared to baseline scores (p = 0.0005). No significant difference was seen in the anxiety scores between the SPA and control groups at six months. Depression decreased in both groups but to a greater degree in the SPA group. A significant difference was seen between the SPA group and control group in terms of depression scores. What the “control” or comparison group was or what care was given to them is not clear.
As reported, patients with non-metastatic breast cancer did not appear to derive significant benefit (improved quality of life as measured by the SF-36) from a two-week SPA intervention in terms of improving quality of life and reducing anxiety and depression.
This unrealistic intervention (two-week SPA stay) does not seem sustainable. Furthermore, if this “intensive” intervention did not demonstrate significant impact on quality of life or anxiety, except for depression, then the “cost” of such an intensive intervention is not worth the benefit. When exactly the intervention occurred is not reported relative to timing of completion of breast cancer treatment except to say “within nine months,” but this is an important variable/covariate because time since treatment completion (and intervention) might impact study results. Importantly, unclear is how subjects were screened or that only a “distressed” group was enrolled. The report that global SF-36 scores at study inclusion were 56 and 54 respectively (treatment and control groups) indicates that this is not a very “stressed” group, as evidenced by SF-36. The higher the scores on the SF-36, the better the quality of life. These scores at study inclusion are right at the midpoint range of 0%–100%; thus, a possible floor effect is at play. Overall, this is not a very well developed or reported study.
No real meaningful nursing implications are drawn from this study. The intervention seems unrealistic and unsustainable and did not impact outcome measures as predicted, except for depression.
Kwekkeboom, K. L., Cherwin, C. H., Lee, J. W., & Wanta, B. (2010). Mind-body treatments for the pain-fatigue-sleep disturbance symptom cluster in persons with cancer. Journal of Pain and Symptom Management, 39, 126–138.
To identify and synthesize the evidence for mind-body interventions for which the evidence suggests benefit for at least two of the three cluster symptoms of pain, fatigue, and sleep disturbance.
Databases searched were CINAHL, MEDLINE, and PsycINFO through March 2009.
Search keywords were guided imagery, hypnosis, relaxation, biofeedback, cognitive behavioral therapy, coping skills training, meditation, virtual reality, music AND cancer AND fatigue, sleep disturbance, sleep difficulty, insomnia, and pain.
Studies were included in the review if they
Studies were excluded if they
A total of 47 studies were identified. In four of those, all testing virtual reality, only the symptom of fatigue was measured, so these were eliminated.
The final sample included 43 studies. Study sample sizes and total patients involved across studies were not reported.
Relaxation
Six studies examined relaxation interventions in hospitalized patients, outpatients with chronic pain, and women with early-stage breast cancer.
Imagery and Hypnosis
Six studies examined imagery and hypnosis.
Cognitive Behavioral Therapy (CBT)/Coping Skills Training (CST)
Twenty-one studies tested CBT/CST.
Meditation
Four studies were included.
Music
Findings of this review were equivocal.
Although the findings did not clearly demonstrate the effects of these interventions across studies, the authors concluded that these interventions hold promise. Although such interventions carry minimal risk to patients, some interventions would require substantial time and resource commitment to provide.
Kwekkeboom, K.L., Wanta, B., & Bumpus, M. (2008). Individual difference variables and the effects of progressive muscle relaxation and analgesic imagery interventions on cancer pain. Journal of Pain and Symptom Management, 36, 604–615.
To assess, among hospitalized patients with cancer-related pain, responses to progressive muscle relaxation (PMR) and analgesic imagery, including the impact of these interventions on pain-related distress and perceived control over pain
To examine the influence of ability, outcome expectancy, previous experience, and concurrent symptoms on the effectiveness of the interventions
Scripts relating to \"control conditions,\" PMR, and guided imagery interventions were recorded on a CD. The recorded voice was male, and the recording did not include music. The day 1 control recording consisted of identification of health team members, explanation of patient rights, and a description of various hospital services. The second control recording described exercise and other activities to maintain strength while hospitalized and presented issues for consideration in discharge planning. The PMR recording guided listeners in tensing and relaxing muscles in a series of 12 major muscle groups from head to feet. The analgesic, or guided imagery, recording asked listeners to scan their bodies to identify areas of pain and to imagine replacing pain with comforting sensations. Then the recording asked listeners to imagine putting their hand in an anesthetic fluid, feeling it go numb, and then transfer the numbness to painful areas of the body. All recordings were of similar length. Trials were done when current pain was rated 2–8 on a 10-point scale. Trials were delayed if patients had received an oral analgesic within one hour or an IV analgesic within 30 minutes. Patients with the option of patient-controlled analgesia were asked to refrain from increasing doses during the 15-minute trial and were maintained on basal continuous infusion. A control trial was the first trial done each day. If pain persisted at the end of the control trial, the research nurse continued with whichever experimental trial was assigned for that day. Two intervention trials were done each day, at least one hour apart. Patients completed pre- and post-trial ratings of pain intensity and related distress. For each outcome measured, scores were averaged across two control, two PMR, and two analgesic imagery trials. In cases where only one trial was completed, this score was used in analysis. Patients were randomly assigned to two different groups. In one group, PMR preceded imagery interventions; in the other, the sequence was reversed. All patients received the same control trials.
The study used a crossover design with control.
In only 50% of patients did PMR and guided imagery appear to have a more positive short-term effect on pain intensity, pain-related distress, and perceived control of pain than did simple distraction. Variables examined did not appear to influence the effects of PMR, but expectations and number of concurrent symptoms appeared to influence the effects of guided imagery.
PMR and analgesic imagery, facilitated by a recording on CD, might be helpful to some patients to reduce short-term pain intensity, decrease pain-related distress, and increase sense of control over pain. However, much more evidence is needed before investigators can draw firm conclusions. These interventions could be implemented easily in a hospital setting and do not appear to harm patients. They appear to be more effective for individuals with greater ability to imagine, greater expectations of effectiveness, and fewer additional symptoms. This fact might lead clinicians to identify that group of patients most likely to benefit from such interventions.
Kwekkeboom, K. L., Abbott-Anderson, K., & Wanta, B. (2010). Feasibility of a patient-controlled cognitive-behavioral intervention for pain, fatigue, and sleep disturbance in cancer. Oncology Nursing Forum, 37, E151–E159.
To evaluate the feasibility of a patient-controlled, cognitive-behavioral intervention for pain, fatigue, and sleep disturbance during treatment for advanced cancer and to assess the initial efficacy of the intervention.
Patients provided baseline measures, such as measures relating to demographics and a symptom inventory, received education, and underwent training to use an mp3 player loaded with 12 cognitive-behavioral strategies (relaxation exercises, guided imagery, nature sounds). Patients used the strategies as needed for symptom management for two weeks and kept a log of symptom ratings with each use. Following the two-week intervention, patients completed a second symptom inventory and an evaluation of the intervention. Clinic staff identified patients who met the eligibility criteria based on diagnosis and treatment and then were briefly introduced to the study and asked if a research nurse could visit to provide additional information. The research nurse met with interested patients, assessed symptoms, and completed eligibility screening. Study purpose and procedures were explained, and written informed consent was obtained.
The study used a one-group, pre- and postintervention design.
The patient-controlled, cognitive-behavioral intervention is feasible and may reduce the day-to-day severity of co-occurring pain, fatigue, and sleep disturbance.
The findings support nurse education and the recommendation of the specified patient-controlled, cognitive-behavioral interventions for the management of pain, fatigue, and sleep disturbance. In regard to patient care and symptom management at all stages of cancer, nurses are the front-line educators of patients. This intervention supports the principle of autonomy for patients able to participate actively in care. Further study—a randomized, controlled trial to test the efficacy of the intervention for co-occurring pain, fatigue, and sleep disturbance—was under way at the time this study was published.
Kwekkeboom, K. L., Abbott-Anderson, K., Cherwin, C., Roiland, R., Serlin, R. C., & Ward, S. E. (2012). Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. Journal of Pain and Symptom Management, 44, 810–822.
To test the effects of a psychoeducational intervention on pain, fatigue, and sleep disturbance.
Patients were randomly assigned to the intervention group or the wait-list control group. The intervention consisted of a single one-on-one training session with a research nurse, which was followed by recorded guidance that provided imagery, relaxation exercises, and nature sounds. Most exercises lasted 20 minutes and were delivered via an mp3 player. The study lasted two weeks.
Patients were undergoing the active antitumor treatment phase of care.
The study used a randomized, controlled trial, pre- and postintervention design.
The intervention demonstrated a small statistically significant effect on the symptoms of pain and fatigue and the overall symptom cluster of pain, fatigue, and sleep disturbance.
The intervention was a relaxation or imagery therapy rather than a true CBT. The intervention was associated with short-term statistically significant benefits, but the actual size of the effect was small. Findings suggested that approaches using relaxation and imagery may result in some small benefit for patients, but the effect was weak.